News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Durvalumab plus radiotherapy shows promise in unresectable NSCLC
17 Sep 2023
In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.
17 Sep 2023

ESBL-producing, gentamicin-resistant UTI more common during first week of life
17 Sep 2023
A recent study provides further evidence to support the current recommendations for empirical intravenous treatment with gentamicin and ampicillin for febrile infants younger than 2 months with suspected urinary tract infection (UTI).
17 Sep 2023






